# US 2016/0355607 A1 · Activation of (na++k+)-atpase inhibits platelet aggregation and prevents thrombosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355607 A1
- Document ID: US20160355607A1
- Status: Published application
- Kind: A1
- Application number: 15/232,773
- Filed: 2016-08-09
- Published: 2016-12-08
- Earliest claimed: 2013-04-04
- Inventors: Kai Yuan Xu
- Web page: https://patentgrep.com/patent/US20160355607A1

## CPC

- C07K 16/40: against enzymes
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 9/14: Hydrolases (3)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/75: Agonist effect on antigen
- C12Y 306/03009: Na+/K+-exchanging ATPase (3.6.3.9)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Methods of inhibiting platelet aggregation using antibodies having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis in a subject using such antibodies.

## Claims

### Claim 1

A method for inhibiting platelet activation and aggregation in a subject comprising administering an effective amount of an antibody having binding specificity for the α subunit of NKA to a subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody has binding specificity for one or more of the peptides represented by SEQ ID NOs:1-5.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody is antibody SSA78 or a humanized or human versions thereof, or a fragment or derivative thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody is antibody SSA401 or a humanized or human versions thereof, or a fragment or derivative thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody is antibody SSA412 or a humanized or human versions thereof, or a fragment or derivative thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody is in a pharmaceutical formulation comprising the antibody and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has or is at greater risk than the general population for a disease or condition selected from the group consisting of venous thrombosis, deep vein thrombosis, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari syndrome, Paget-Schroetter disease, cerebral venous sinus thrombosis, cavernous sinus thrombosis, arterial thrombosis, stroke, pulmonary embolism, coronary heart disease, angina, heart failure, heart valve disease, atherosclerosis, a myocardial infarction, and post-surgical thrombotic complications arising from angioplasty and organ transplantation.

### Claim 8

A method for inhibiting thrombosis in a subject comprising administering an effective amount of an antibody having binding specificity for the α subunit of NKA to a subject in need thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the antibody has binding specificity for one or more of the peptides represented by SEQ ID NOs:1-5.

### Claim 10 (depends on 8)

The method of claim 8, wherein the antibody is antibody SSA78 or a humanized or human versions thereof, or a fragment or derivative thereof.

### Claim 11 (depends on 8)

The method of claim 8, wherein the antibody is antibody SSA401 or a humanized or human versions thereof, or a fragment or derivative thereof.

### Claim 12 (depends on 8)

The method of claim 8, wherein the antibody is antibody SSA412 or a humanized or human versions thereof, or a fragment or derivative thereof.

### Claim 13 (depends on 8)

The method of claim 8, wherein the antibody is in a pharmaceutical formulation comprising the antibody and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 8)

The method of claim 8, wherein the subject has or is at greater risk than the general population for a disease or condition selected from the group consisting of venous thrombosis, deep vein thrombosis, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari syndrome, Paget-Schroetter disease, cerebral venous sinus thrombosis, cavernous sinus thrombosis, arterial thrombosis, stroke, pulmonary embolism, coronary heart disease, angina, heart failure, heart valve disease, atherosclerosis, a myocardial infarction, and post-surgical thrombotic complications arising from angioplasty and organ transplantation.

### Claim 15

A method for treating a disease of disregulated platelet aggregation in a subject comprising administering an effective amount of an antibody having binding specificity for the α subunit of NKA to a subject in need thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the antibody has binding specificity for one or more of the peptides represented by SEQ ID NOs:1-5.

### Claim 17 (depends on 15)

The method of claim 15, wherein the antibody is antibody SSA78 or a humanized or human versions thereof, or a fragment or derivative thereof.

### Claim 18 (depends on 15)

The method of claim 15, wherein the antibody is antibody SSA401 or a humanized or human versions thereof, or a fragment or derivative thereof.

### Claim 19 (depends on 15)

The method of claim 15, wherein the antibody is antibody SSA412 or a humanized or human versions thereof, or a fragment or derivative thereof.

### Claim 20 (depends on 15)

The method of claim 15, wherein the antibody is in a pharmaceutical formulation comprising the antibody and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 15)

The method of claim 15, wherein the disease of dysregulated platelet aggregation is selected from the group consisting of hypercoagulability, essential thrombocythemia, reactive thrombocytosis, thrombocytopenia, von Willebrand disease, a hereditary intrinsic platelet disorder, and an acquired disorder of platelet function.
